Immuno-Biological Laboratories Co., Ltd. (JP:4570)
:4570
Want to see JP:4570 full AI Analyst Report?
4570 Stock Chart & Stats
¥1404.00
¥18.00(3.96%)
At close: 4:00 PM EST
¥1404.00
¥18.00(3.96%)
Day’s Range― - ―
52-Week Range¥450.00 - ¥3,820.00
Previous CloseN/A
Volume75.00K
Average Volume (3M)23.51K
Market Cap
¥12.65B
Enterprise Value¥12.21B
Total Cash (Recent Filing)¥903.75M
Total Debt (Recent Filing)¥196.94M
Price to Earnings (P/E)41.4
Beta0.94
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.44
Shares Outstanding9,314,590
10 Day Avg. Volume28,690
30 Day Avg. Volume23,506
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)2.95
Price to Sales (P/S)4.61
P/FCF Ratio36.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross And Net MarginsSustained high gross (64.8%) and net (25.7%) margins indicate durable pricing power and efficient cost structure in reagents and assay kits. These margins generate internal funds to support R&D, validation, and recurring product supply, helping the company reinvest and withstand cyclical demand shifts.
Conservative Balance SheetVery low leverage (debt-to-equity 0.13) and an 82% equity ratio provide financial flexibility to fund capex, capacity expansion or strategic deals without stressing cash flows. This capital structure reduces refinancing risk and enhances resilience through funding-cycle variability in life-science markets.
Improving Cash GenerationA 0.74 OCF-to-net-income ratio and rising operating cash flow show the company converts profit into cash effectively. Strong cash conversion supports working capital for consumable sales, funds product development and validation cycles, and lowers reliance on external financing over medium term.
Bears Say
Modest Revenue GrowthRevenue growth near 8.8% is modest for the biotechnology/reagent segment and may limit the pace at which the company achieves scale benefits. Slower top-line expansion can constrain faster product investment, geographic rollouts, and the ability to dilute fixed R&D and manufacturing costs over time.
Small Organizational ScaleA headcount of 57 signals limited internal capacity for simultaneous R&D, commercial expansion and manufacturing scale-up. Small size increases execution risk, makes geographic expansion harder, and raises dependence on a few key personnel or third-party partners for growth and continuity.
Limited Forward DisclosureAbsence of guidance and minimal earnings-call disclosure reduces stakeholder visibility into future performance and planning. This limited communications approach can hinder long-term partner planning, investor confidence and the market's ability to assess strategy execution over multiple quarters.
4570 FAQ
What was Immuno-Biological Laboratories Co., Ltd.’s price range in the past 12 months?
Immuno-Biological Laboratories Co., Ltd. lowest stock price was ¥450.00 and its highest was ¥3820.00 in the past 12 months.
What is Immuno-Biological Laboratories Co., Ltd.’s market cap?
Immuno-Biological Laboratories Co., Ltd.’s market cap is ¥12.65B.
When is Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date?
Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date is May 20, 2026 which is in 17 days.
How were Immuno-Biological Laboratories Co., Ltd.’s earnings last quarter?
Immuno-Biological Laboratories Co., Ltd. released its earnings results on Feb 12, 2026. The company reported ¥11.44 earnings per share for the quarter, beating the consensus estimate of N/A by ¥11.44.
Is Immuno-Biological Laboratories Co., Ltd. overvalued?
According to Wall Street analysts Immuno-Biological Laboratories Co., Ltd.’s price is currently Overvalued.
Does Immuno-Biological Laboratories Co., Ltd. pay dividends?
Immuno-Biological Laboratories Co., Ltd. pays a Notavailable dividend of ¥6 which represents an annual dividend yield of N/A. See more information on Immuno-Biological Laboratories Co., Ltd. dividends here
What is Immuno-Biological Laboratories Co., Ltd.’s EPS estimate?
Immuno-Biological Laboratories Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immuno-Biological Laboratories Co., Ltd. have?
Immuno-Biological Laboratories Co., Ltd. has 9,314,590 shares outstanding.
What happened to Immuno-Biological Laboratories Co., Ltd.’s price movement after its last earnings report?
Immuno-Biological Laboratories Co., Ltd. reported an EPS of ¥11.44 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 7.396%.
Which hedge fund is a major shareholder of Immuno-Biological Laboratories Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4570
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immuno-Biological Laboratories Co., Ltd.
Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer's disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtration high performance liquid chromatography method that can profile various clinical samples, such as tiny plasma or serum samples from both small animals and human beings for broad range of research fields including lipid metabolism, development of drugs for life-style related diseases, development of functional supplemental foods, and clinical studies. In addition, the company offers LipoTEST, a support tool for diagnostic and health checks at animal clinics; and customized biomarker testing services for Life-style related diseases. Further, it operates protein production business using transgenic silkworms for manufacturing of antibodies for research reagents and diagnostic products; human collagen for cosmetic materials; development of proteins for use in drugs; and other proteins production. The company was incorporated in 1982 and is headquartered in Fujioka, Japan.
Technical Analysis
StemRIM Inc.
―
Takara Bio Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―